Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Atezolizumab (Primary) ; CDX 1401 (Primary) ; Poly ICLC
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Jun 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 05 May 2016 Status changed from not yet recruiting to recruiting.
- 15 Jul 2015 New trial record